Day: April 6, 2021

  Roissy, 6 April 2021 Air France-KLM announces a plan of capital-strengthening measures with the objective of strengthening its balance sheet, preparing the recovery and repositioning the Group on a sustainable financial trajectoryAir France-KLM (“the Group”) announces the following measures in relation to Air France, which have been approved by the European Commission in its decision to authorize a €4 billion French State measures to recapitalise Air France and its Holding company: A capital increase for an amount up to €1 billion, with a priority subscription period for shareholders, subject to market conditions and the prior approval on the prospectus by the Autorité des marchés financiers (the “AMF”) and,  Simultaneously, conversion of the €3 billion French State direct loan drawn into  perpetual hybrid bonds instrument. The...

  Roissy, 6 avril 2021 Air France-KLM annonce un plan de mesures de renforcement du capital avec pour objectif de renforcer son bilan, de préparer la reprise et de repositionner le groupe sur une trajectoire financière durableLe Groupe Air France-KLM annonce les mesures suivantes concernant Air France, qui ont été approuvées par la Commission européenne dans sa décision d’autoriser une opération de 4 milliards d’euros de l’Etat français pour recapitaliser Air France et sa Holding : Une augmentation de capital d’un montant maximum de 1 milliard d’euros, avec une période de souscription prioritaire pour les actionnaires, sous réserve des conditions de marché et de l’approbation préalable du prospectus par l’Autorité des marchés financiers (l'”AMF”) et,  Simultanément, la conversion du...

                                                                                                                                                                                                                                                                                                                 PRESS RELEASE AB SCIENCE ANNOUNCES COLLABORATION WITH THE UNIVERSITY OF CHICAGO TO CONDUCT RESEARCH FOR THE PREVENTION AND TREATMENT OF COVID-19 WITH MASITINIB AND OTHER AB SCIENCE PROPRIETARY DRUGS Paris, April 6 2021, 8am CET AB Science SA (Euronext – FR0010557264 – AB), together with the University of Chicago, today announces the signing of an exclusive licensing agreement for conducting research on the prevention and treatment of humans infected with nidoviruses, coronaviruses and picornaviruses. This collaboration follows...

                                                                                                                                                                                                                                                                                               COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE LA SIGNATURE D’UNE COLLABORATION DE RECHERCHE AVEC L’UNIVERSITE DE CHICAGO SUR LA PREVENTION ET LE TRAITEMENT DE LA COVID-19 AVEC LE MASITINIB ET D’AUTRES MEDICAMENTS BREVETES PAR AB SCIENCE Paris, 6 avril 2021, 8h AB Science SA (Euronext – FR0010557264 – AB) et l’Université de Chicago annoncent aujourd’hui la signature d’un accord de licence exclusif pour mener des recherches sur la prévention et le traitement des humains infectés par des nidovirus, coronavirus et picornavirus. Cette collaboration...

Leuven, BE, Boston, MA, US – April 6, 2021 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care back of the eye therapies, today announces that is has agreed to a capital commitment of up to €30 Million with Negma Group. Negma Group is a Paris-based leading financial institution focused on supporting growth and capturing value through a multi-strategy approach. Negma Group has committed to subscribe to up to €30 million in equity in tranches over a 12-month period through mandatory convertible bonds at Oxurion’s sole discretion. Oxurion anticipates initial clinical data from its lead drug candidate THR-149 later this year. THR-149 is a plasma kallikrein inhibitor being developed as a potential new standard of care for diabetic macular edema (DME) patients, who respond...

NANTES, France, April 06, 2021 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the first peer-reviewed publication on OSE-230, a novel and innovative approach in the management of the resolution of chronic and severe inflammation, in Science Advances. The article, entitled: “Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution” (1) reports on the discovery and preclinical data for OSE-230, an innovative agonist antibody against ChemR23, also known as chemerin chemokine-like receptor 1 (CMKLR1), a G-protein coupled receptor (GPCR) expressed on myeloid immune cells known to modulate inflammation. OSE Immunotherapeutics’ R&D team identified ChemR23 as a GPCR receptor of the resolution program overexpressed in the inflamed tissues of patients...

BASKING RIDGE, N.J., April 06, 2021 (GLOBE NEWSWIRE) — The 5G Future Forum, the global industry group focused on driving rapid adoption of 5G and Multi-access Edge Computing (“MEC”), today announced their call for new members, specifically targeting mobile network operators. The application period begins on April 6, 2021.  The 5G Future Forum (5GFF) was established in January 2020 by América Móvil, KT Corp., Rogers, Telstra, Verizon, and Vodafone to develop 5G interoperability specifications to accelerate the delivery of 5G and MEC solutions around the world. The 5G Future Forum focuses on the global service delivery and the interoperable availability specifications to improve speed to market for developers and multinational enterprises working on 5G-enabled solutions. The Forum’s work will support development of public and private...

加州爱莫利维尔, April 06, 2021 (GLOBE NEWSWIRE) — 今天，数字细胞生物学领域的龙头企业Berkelly Lights, Inc.（纳斯达克股票代码: BLI）宣布推出Opto Assure，这是细胞系开发前期提供产量和产品质量数据的一系列分析方法。第一个系列可直接检测产品总量，通过在抗体治疗开发过程中尽早评估生物治疗蛋白质的质量，确保快速推进批量生产。通过Opto Assure，客户可快速选择具有良好可制造性配置的克隆细胞系列，从而降低扩容成本，并改善下游产品。 随着复杂抗体治疗方式的出现，细胞系开发变得更具挑战性。这些精心设计的蛋白质容易出现质量问题（包括聚合、副产品和转化后的修饰），这些问题会影响药物的可制造性、保质期和安全性。Berkelley Lights在克隆选择过程中超越了效价评估，从而巩固了其在细胞系开发方面的技术领导地位。通过早期识别出具有高产量和所需质量的秘密产品克隆细胞，Opto Assure有助于最大限度地降低后期代价高昂的失效风险。 Berkelly Lights抗体疗法高级副总裁John Proptor博士说：“我们很高兴能够授权双特异性抗体等复杂疗法的制造商更快地开发更好的细胞系的生产。我们推出Opto Assure系列的目的是提高客户的生产能力，进一步减少用于防止下游产品失效的资源，并确保更加高效的工艺过程。” 关于Berkeley LightsBerkeley Lights是一家领先的数字细胞生物学公司，致力于促进和加速生物治疗剂及其他基于细胞的产品的快速开发和商业化。Berkelley Lights平台能同时捕获成千上万的单个细胞的深表型、功能型和基因型信息，能以最佳细胞形式为客户提供期望的活生物。我们的平台是一种全集成端对端解决方案，采用专有耗材，包括我们的OptoSelect™芯片和试剂套件、以及先进的自动化系统和应用软件。我们开发的Berkeley Lights平台可提供最先进的环境，确保上规模单细胞的快速功能特征化，其目标是在整个细胞类产品价值链中，为客户制定一种行业标准。 前瞻性声明鉴于本新闻稿中包含的声明不是对Berkeley...

加州愛莫利維爾, April 06, 2021 (GLOBE NEWSWIRE) — 數碼細胞生物學領域的領導者 Berkeley Lights, Inc. (Nasdaq: BLI) 今天宣佈推出 Opto Assure，這是一系列測定方法，可在細胞系開發的早期階段提供產量及產物品質數據。該系列的第一個方法可直接檢測產物聚合，確保在抗體治療藥物開發流程中更快評估生物治療蛋白質的品質，以更快投入批量生產。憑藉 Opto Assure，客戶可以快速選擇具有良好可製造性特徵的克隆細胞系，從而降低擴大規模的成本並獲得更出色的下游產品。 隨著複雜抗體治療形式出現，細胞系的開發變得更具挑戰性。這些經過高度工程改造的蛋白質容易出現品質問題，包括聚合、副產物及轉化後的改造，進而影響藥物可製造性、保質期及安全性。Berkeley Lights 在克隆選擇流程中的效價評估上更進一步，從而提高其在細胞系開發領域的技術領導者地位。Opto Assure 透過儘早識別可分泌高產量及所需品質產物的克隆產品，將昂貴的後期失敗風險降至最低。 Berkeley Lights 抗體治療藥物副總裁 John Proctor 博士表示：「我們很高興能夠使複雜治療藥物（例如雙特異性藥物）的製造商以更快速度開發更出色的生產細胞系。隨著我們增建 Opto Assure 系列產品，客戶可以期待新增的功能，這些功能可進一步減少用於預防下游產品失敗的資源，並確保流程更高效。」 關於 Berkeley LightsBerkeley Lights 是一家領先的數碼細胞生物學公司，致力為客戶實現及加速生物治療藥物及其他細胞產品的快速開發及商業化。Berkeley Lights Platform 同時為數千個單細胞擷取深入的表型、功能及基因型資訊，還能以最佳細胞的形式滿足客戶的實時生物學需求。我們的平台是由專有消耗品組成的全面整合端到端解決方案，包括 OptoSelect™ 晶片及試劑盒、高級自動化系統及應用程式軟件。我們開發了...